Dec 28, 2024, 15:55
Chris Boerner: The FDA approved our new subcutaneous immunotherapy treatment
Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, posted on LinkedIn:
“Today, the FDA approved our new subcutaneous immunotherapy treatment that offers a patient-centric experience. This is remarkable work that can positively impact the lives of patients with certain types of cancer. Congratulations to my colleagues across Bristol Myers Squibb whose relentless pursuit of bold science contributed to this achievement. Looking forward, we will continue to set the bar even higher because, together, we are defining what’s possible for the future of science and the patients we serve.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 31, 2025, 22:43
Jan 31, 2025, 22:43
Jan 31, 2025, 22:43
Jan 31, 2025, 22:43